Objectives: The aim of this study was to identify patients with esophageal cancer who may benefit from induction chemotherapy (IC) before neoadjuvant chemoradiotherapy (nCRT) on the basis of a prognostic scoring model.
Introduction
Esophageal cancer (EC) is an aggressive disease and remains a significant health problem in the United States, with an estimated 16,910 new cases and 15,690 deaths in 2016. 1 In patients with locally advanced *Corresponding author.
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esophageal or gastroesophageal junction (GEJ) carcinomas, neoadjuvant chemoradiotherapy (nCRT) followed by surgery has been shown to improve locoregional control and overall survival (OS) compared with surgery alone. [2] [3] [4] However, despite the advances in neoadjuvant therapy, EC remains associated with poor outcome, with 5-year OS rates of 25% to 47%. 4, 5 In addition, more than 40% of patients experience recurrence after trimodality therapy. 4, 6 Therefore, other intensive treatment modalities are greatly needed.
Because it is likely that many patients harbor micrometastases even at the time of diagnosis, the addition of induction chemotherapy (IC) before nCRT could potentially improve clinical outcomes by addressing occult micrometastases at an earlier stage. Several retrospective studies have suggested that IC before nCRT could significantly improve pathologic complete response (pCR), OS, and disease-free survival (DFS), especially in the subset of patients with advanced disease. 7, 8 Most single-arm phase II trials have demonstrated the feasibility and efficacy of IC, [9] [10] [11] but somewhat disappointingly, two randomized phase II trials have failed to demonstrate a clear benefit of IC in EC. 12, 13 Unfortunately, these studies were relatively small clinical trials conducted in an unselected patient population.
We hypothesize that IC may provide a selective clinical benefit for higher-risk patients with EC. Therefore, the aim of this study was to construct a prognostic scoring model using a large cohort of patients to identify patients who may benefit from IC before nCRT.
Patients and Methods

Patient Population
We retrospectively analyzed 1582 consecutive patients with EC from our prospectively maintained database who were received CRT with or without an operation at The University of Texas M. D. Anderson Cancer Center between January 1998 and July 2015 (Fig. 1) . The inclusion criteria were as follows: (1) histologic documentation of esophageal adenocarcinoma or squamous cell carcinoma (SCC), (2) thoracic EC or GEJ carcinoma, (3) T1Nþ or T2-4aN any , (4) radiation dose of at least 40 Gy with concurrent chemotherapy followed by surgery, (5) staging with baseline positron emission tomography/computed tomography (PET/CT), (6) no history of a concomitant malignancy, and (7) complete and retrievable clinical records. Patients with T1N0 stage, cervical EC, or any M1 disease were excluded. The institutional review board approved this study. 
Pretreatment Work-up
Pretreatment work-up included physical examination, standard laboratory tests, esophagogastroduodenoscopy with endoscopic ultrasound (EUS) and biopsies, pulmonary function tests, chest/abdominal CT with contrast, and PET/CT. Tumors were staged and/or restaged according to the seventh TNM staging system of the American Joint Committee on Cancer.
14 At our institution, the histologic grading is based on the WHO classification of tumors of the digestive system and the reporting pathologic findings are based on the College of American Pathologists Cancer Protocols. 15, 16 For SCC, the histologic grades are classified as Gx (grade cannot be assessed), G1 (well differentiated), G2 (moderately differentiated), and G3 (poorly differentiated). Adenocarcinomas are graded as Gx, G1, G2, or G3 according to the proportion of tumor composed of glands. If there are variations in the differentiation within the tumor, the highest grade is recorded. Generally, the specimens are reviewed by one pathologist to define the histologic subtype and grade, which are then be confirmed by another senior pathologist. For difficult diagnostic cases, the slides are reviewed collectively by a group of experienced pathologists.
A lymph node was considered positive if it was fluorodeoxyglucose avid on PET/CT, had a short axis (1 cm), or was histologically confirmed by EUS-guided fine-needle aspiration. The size of the lymph node was measured in the short axis by one experienced radiologist on the axial CT images. For patients with multiple positive lymph nodes, the short diameter of the largest lymph node was recorded for analysis. All patients were evaluated by a multidisciplinary team before treatment according to institutional practice guidelines.
Therapy
All patients received concurrent chemotherapy during radiotherapy, and a fraction of patients received IC before nCRT. As previously described, IC regimens still generally comprise a fluoropyrimidine (5-fluorouracil or capecitabine), a platinum agent, and/or a taxane. 6 Radiation was delivered by using three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), or proton beam therapy. Typically, the prescribed dose was 50.4 Gy in 28 fractions given 5 days per week. During radiotherapy, patients typically received concurrent platinum-or taxane-based chemotherapy with fluorouracil.
All patients underwent clinical restaging approximately 4 to 6 weeks after the completion of CRT. Esophagectomy was performed with a transthoracic (Ivor-Lewis), transhiatal, minimally invasive, or threefield technique as determined by the operating team. R0 resection was defined as the absence of malignancy on histopathologic examination of proximal, distal, and circumferential margins. A pCR was defined as the absence of cancer cells in all examined tissues.
Follow-up
All patients were followed every 3 months for the first year, every 6 months for the next 2 years, and then annually. Follow-up examinations included physical examination, blood tests, chest/abdominal CT, periodic esophagogastroduodenoscopies with biopsies, and/or PET/CT. Survival follow-up was conducted by using electronic medical records and our institution's tumor registry. The data were updated in August 2016 for censored data analysis.
Statistical Analysis
Age and primary tumor length were grouped by the median value as a cut-off. Baseline maximum PET standard uptake (SUV max ) values were grouped according to the cut-off of receiver operating characteristic curve analysis. Grouping by lymph node size was performed by using published thresholds. 17 Categorical variables were compared by using the chi-square test or Fisher's exact test. Locoregional recurrences (LRRs) were defined as recurrences within the esophagus or regional lymph nodes. Distant recurrences were defined as nonregional lymph node recurrences or any systemic metastases. DFS was calculated from the date of diagnosis to the date of recurrence, death, or last follow-up. OS was determined until death or last follow-up.
Propensity score matching (PSM) analysis was conducted to reduce the effects of potential confounding factors in the comparison of survival between treatment groups at a ratio of 1:1. The Kaplan-Meier method was used to analyze DFS and OS, the Breslow test was used to examine the differences between groups, and a Cox proportional hazards regression model was used in multivariate analysis to determine independent pretreatment risk factors for DFS (backward stepwise). A prognostic scoring system was developed on the basis of significant variables obtained from the multivariate analysis. The score was the weighted sum of the variables in which the weights were defined as the quotient of the corresponding estimated coefficient divided by the smallest chi-square coefficient. 18 Statistical analyses were performed with SPSS 22.0 software (IBM Corp., Armonk, NY) and Stata 12 software (StataCorp, College Station, TX). A p value less than 0.05 was considered statistically significant. with EC who met the selection criteria were selected for analysis, including 218 patients undergoing IC before nCRT (IC group) and 317 patients who did not receive IC (non-IC group). The median age was 60 years (range 21-82).
Results
Patient and Tumor Characteristics
The median length of the primary tumor was 5.0 cm (range 0.4-14.0); tumors were overwhelmingly located in the distal esophagus or GEJ (94.6%). The median radiation dose was 50.4 Gy (range 43.2-63.0). Most patients (89.0%) received five cycles of weekly concurrent chemotherapy. Patients treated with IC received a median of two cycles (range one-10) of chemotherapy before nCRT, with 72.5% of them receiving two cycles. As shown in Table 1 , patients with bulky tumors, advanced T or N stage, adenocarcinomas, and high baseline PET SUV max values were more likely to receive IC. Additionally, more patients received 3DCRT in the IC group, whereas more patients received IMRT or proton therapy in the non-IC group. After nCRT, R0 resection was achieved in 95.0% of patients in the IC group and 94.3% in the non-IC group (p ¼ 0.751). After surgery, 61 patients in the IC group (28.0%) achieved a pCR compared with 76 patients (24.0%) in the non-IC group (p ¼ 0.297).
Follow-up and Survival
The median follow-up period was 41.8 months (range 4.8-178.5) for the entire cohort and 63.5 months (range 8.0-178.5) for survivors. At the time of final analysis, 251 patients (46.9%) had died. The IC group demonstrated a trend toward a lower LRR rate (12.8% vs. 18.6%, p ¼ 0.076) and a similar distant recurrence rate (38.5% vs. 37.5%, p ¼ 0.816) compared with the non-IC group. The 5-year DFS rate favored the IC group without statistical significance (53.7% vs. 45.1%, p ¼ 0.196) (Fig. 2A) . The 5-year OS rates in the IC and non-IC groups were comparable (55.5% vs. 54.0%, p ¼ 0.792) (Fig. 2B ).
Univariate and Multivariate Analysis
Because it appears that IC has a more profound effect on DFS than OS, we went on to identify factors that would risk-stratify patients on the basis of DFS. For the entire cohort, univariate analysis identified pretreatment factors such as histologic grade, tumor location, primary tumor length, nontraversability by EUS, T stage, N stage, baseline PET SUV max , maximum lymph node diameter, and distant lymph node metastases significantly affecting DFS (Table 2) . By multivariate analysis, the following four factors remained independent predictors for DFS: histologic grade (G3 vs. Gx/G1/G2), tumor location (upper/ middle esophagus vs. distal esophagus/GEJ), baseline PET 
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SUV max (5.3 vs. <5.3), and maximum lymph node diameter (1.0 cm vs. <1.0 cm). Because the radiotherapy modalities (3DCRT vs. IMRT vs. proton) were not balanced between the two treatment groups (p ¼ 0.019), we further performed univariate analysis to investigate the effect of different radiotherapy modalities on survival. Univariate analysis indicated that radiotherapy modality was neither associated with DFS (p ¼ 0.354) nor OS (p ¼ 0.286) in the whole cohort.
Prognostic Scoring Model
As shown in Table 2 , the risk score of each variable was calculated according to its relative contribution in the Cox proportional hazards model as determined by the chi-square score. A prognostic scoring system was then constructed by using the four prognostic factors, and the score was derived by adding the value of each factor, leading to a range of the total score from 0 to 6.2. By applying the median value as a cut-off point, two risk groups were stratified: low-risk (3.5) and high-risk (>3.5). The low-risk patients (n ¼ 412) demonstrated a significantly better DFS than the high-risk patients (n ¼ 123), with 5-year DFS rates of 53.3% and 34.0%, respectively (p < 0.001) (Fig. 3A) . The OS was also significantly better in the low-risk group compared with in high-risk group (p < 0.001) (Fig. 3B) .
Stratification Survival Analysis in High-Risk Patients
The benefits of IC were evaluated in the different risk groups. For the unadjusted high-risk patients (n ¼ 123), the pCR rate was higher in the IC group than in the non-IC group but the difference was not statistically significant (25.8% vs. 17.5%, p ¼ 0.272). LRR was observed in nine patients (13.6%) in the IC group and 13 patients (22.8%) in the non-IC group, respectively (p ¼ 0.239). No significant differences were found in the distant recurrence rates between the groups (53.0% vs. 54.4%, p ¼ 0.88). Patients receiving IC had a significantly better 5-year DFS rate than patients treated without IC (40.4% vs. 26.8%, p ¼ 0.03) (Fig. 4A) . The 5-year OS rate was also higher in the IC group than in the non-IC group, but the difference was 1A, Supplementary Data 3) . For the PSM analysis in high-risk patients, 43 patients receiving IC were identified and matched with 43 patients without IC on the basis of their propensity score of pretreatment factors and radiotherapy modalities (see Table 1 , Supplementary Data 1). After adjustment, prognostic factors were comparable between treatment groups, and the 5-year DFS rate of the IC group was dramatically higher than that of the non-IC group (42.5% vs. 13.9%, p ¼ 0.02) (Fig. 4B) . The OS curves also demonstrated a trend toward improvement in the IC group compared with in the non-IC group 
Stratification Survival Analysis of Low-Risk Patients
For low-risk patients (n ¼ 412), the respective pCR rates, LRR rates, and distant recurrence rates were comparable in both the IC and the non-IC groups before adjustment (28.9% vs. 25.4%, p ¼ 0.43; 12.5% vs. 17.7%, p ¼ 0.163; and 32.2% vs. 33.8%, p ¼ 0.738,). In addition, IC did not provide a clear survival benefit in this cohort, with 5-year DFS rates of 59.4% in the IC group and 49.1% in the non-IC group, respectively (p ¼ 0.231) (Fig. 4C) . There was also no significant difference in 5-year OS rates: 62.7% for the IC group and 60.0% for the non-IC group, respectively (p ¼ 0.929 [see Fig. 1C, Supplementary Data 3] ).
In this population, pretreatment characteristics and treatment modalities were not balanced between groups (see Table 2 , Supplementary Data 2) . For the PSM analysis, 92 patients who received IC were matched with 93 patients who were treated without IC. The DFS was still comparable between the two groups after adjustment, with 5-year DFS rates of 62.2% in the IC group and 68.8% in the non-IC group, respectively (p ¼ 0.178) (Fig. 4D) . Interestingly, the 5-year OS rate was even worse in the IC group as compared with in the non-IC group (65.0% vs. 76.6%, p ¼ 0.038 [see Fig. 1D , Supplementary Data 3] ).
Subgroup Analysis of Adenocarcinoma
Because most patients in the current study (94.4%) had adenocarcinomas, further validation in this subgroup was performed. According to the prognostic scoring system, patients with adenocarcinoma were divided into two groups, with 110 patients in the highrisk group and 395 patients in the low-risk group. For high-risk adenocarcinomas, the IC group showed remarkably better DFS than the non-IC group (p ¼ 0.025 [see Fig. 2A, Supplementary Data 4] ). Moreover, although without statistical difference, the 5-year OS rates also favored the IC group compared with the non-IC group (42.3% vs. 24.3%, p ¼ 0. 
Discussion
Despite the high risk of distant metastasis for patients with EC after definitive therapy, the role of IC before nCRT is not well defined. Using a prognostic scoring model to stratify patients into low-risk and high-risk groups on the basis of DFS, we demonstrated that although IC may not benefit all patients with EC, it may provide benefit to only the selected high-risk patients. Our prognostic scoring model may be a useful tool in selecting patients who may benefit from IC. These data are encouraging but will need to be validated by prospective clinical trials.
Although TNM staging is widely used to predict patient outcome and guide clinical decision making, accumulating data suggest that the current TNM staging system has several limitations in predicting prognosis for patients with EC who are undergoing CRT. 19 Because the measurement of OS is potentially affected by salvage therapies after recurrence, DFS is a valid surrogate end point for OS in many patients with solid tumors. 20 We therefore used DFS as the main end point to develop the simple scoring model in the current study. The four prognostic parameters included in the model are commonly obtained in the clinic, and the simple score calculation could be easily used for clinical implementation or for clinical trial design.
As previously reported, histologic grade is a significant prognostic factor for patients with EC who are undergoing an operation alone. 21 Ajani et al. reported that poorly differentiated histologic grade was associated with a decreased chance of achieving a pCR in patients with EC who are receiving nCRT. 22 Accordingly, we have also identified histologic grade as an independent predictor of DFS. Numerous studies have investigated the prognostic value of PET imaging in EC, including baseline PET SUV max , PET response to CRT, and the relative reduction of SUV. 23 Because the SUV value is associated with tumor metabolic activity, the baseline SUV max may predict biologic behavior, treatment response, and survival. Suzuki et al. studied 209 patients with EC treated with definitive CRT, and their results indicated that a higher baseline SUV max (12.7) was correlated with worse survival. 24 A more recent study from this group reported that OS was similar between CRT alone and trimodality therapy in the subset of patients with EC with baseline SUV max values lower than 6.0. 25 Our findings were in concordance with these previous reports that a higher baseline SUV max is predictive of worse survival in EC.
The prognostic value of lymph node size in EC has been investigated as well. For example, Dhar et al. reported that lymph node size was a significant predictor for survival in patients with EC who are undergoing an operation alone. 17 Nomura et al. reported that in patients receiving definitive CRT alone, lymph node size was also a strong independent prognostic factor. 26 The correlation between lymph node size and survival was confirmed by our results as well, suggesting that lymph node size may be an important prognostic factor in spite of the treatment modality. However, it should be noted that the cut-off values of lymph node size were not the same among these studies, ranging from 0.5 cm to 2.8 cm. 17, 26 For instance, Nomura et al. indicated that a lymph node size of 2.8 cm or larger predicted for the worst prognosis in esophageal SCC. 26 This discrepancy may be due to differences in histologic grade, sample size, and clinical stage distribution among the various studies.
It has been repeatedly demonstrated that pCR is associated with favorable prognosis in EC treated with nCRT followed by an operation. 27 The addition of IC before nCRT may yield survival benefits by increasing pCR rate. Although our findings demonstrated no obvious survival advantage with IC in the unselected EC population, the fact that both DFS and OS in the IC group were not inferior compared with in the non-IC group despite significantly worse baseline characteristics is somewhat telling. Furthermore, after stratification of high-risk patients with use of our prognostic scoring model, IC did result in a higher pCR rate, a lower LRR rate, a similar distant recurrence rate, and significantly improved DFS compared with in the non-IC group. Therefore, the improved DFS in high-risk patients receiving IC seems to be primarily a result of improved locoregional control as reflected by an improved pCR rate and a lower LRR rate. IC failed to demonstrate any statistically significant benefit in low-risk patients compared with in high-risk patients. Somewhat surprisingly, IC failed to provide any significant improvement in distant recurrence in both risk groups, suggesting that distant recurrence remains the biggest challenge in the treatment of EC. Therefore, further development of new strategies to reduce distant failure is much needed.
Given the retrospective nature of this singleinstitutional study, selection bias is inherent in our study population. For instance, high-risk patients were more likely to receive IC on account of bias of the treating physicians, thereby resulting in an imbalance in the baseline characteristics between the IC and the non-IC groups. We attempted to mitigate this limitation by using PSM analysis in the different risk groups, but this did result in smaller numbers of patients for analysis and decreased power. For example, despite a rather large absolute difference in 5-year OS rates favoring the IC group in high-risk patients after adjustment (41.2% vs. 25.0%), the results did not meet statistical significance (p ¼ 0.192). Moreover, the diversity of chemotherapy regimens and radiotherapy modalities in the whole cohort may result in some potential biases on outcomes. However, the effect of radiotherapy modalities on survival is likely to be minimal because of the nonsignificant results in univariate analysis. Lastly, it is difficult to generalize our findings to esophageal SCC given the limited number of cases examined.
